Women with diabetes are 14 percent less likely to be screened for breast cancer compared to women without diabetes, according to a study. "Managing the demands of a chronic condition such as diabetes is challenging for many women, leaving other preventative actions, like screening for cancer, to fall by the wayside," said a physician and author. "Our study found having diabetes posed a significant barrier to breast cancer screening even after considering a woman's socioeconomic status, a known contributor to disparities in care among women."
Women with diabetes are 14 percent less likely to be screened for breast cancer compared to women without diabetes, according to a study by researchers at the Institute for Clinical Evaluative Sciences (ICES) and Women's College Hospital.
The study, published today in the journal Diabetic Medicine, is the first to examine the influence of socioeconomic status on the gap in mammogram screening among women with diabetes.
"Managing the demands of a chronic condition such as diabetes is challenging for many women, leaving other preventative actions, like screening for cancer, to fall by the wayside," said Dr. Lorraine Lipscombe, a staff physician at Women's College Hospital and an adjunct scientist at ICES. "Our study found having diabetes posed a significant barrier to breast cancer screening even after considering a woman's socioeconomic status, a known contributor to disparities in care among women."
Read the entire report here:
Source: ScienceDaily
Oncology Onward: A Conversation With Penn Medicine's Dr Justin Bekelman
December 19th 2023Justin Bekelman, MD, director of the Penn Center for Cancer Care Innovation, sat with our hosts Emeline Aviki, MD, MBA, and Stephen Schleicher, MD, MBA, for our final episode of 2023 to discuss the importance of collaboration between academic medicine and community oncology and testing innovative cancer care delivery in these settings.
Listen
Trastuzumab Deruxtecan Receives FDA Approval for HER2-Positive Solid Tumors
April 5th 2024FDA granted accelerated approval to trastuzumab deruxtecan-nxki for adult patients with unresectable or metastatic HER2-positive solid tumors who received prior systemic treatment and have no satisfactory alternative treatment options.
Read More